Table 1.

Food and Drug Administration–approved immune checkpoint inhibitors and timing of approval

Immune Checkpoint InhibitorYear of ApprovalIndication
CTLA-4 inhibitor
Ipilimumab2011Melanoma, renal cell carcinoma; in combination with nivolumab in CRC
PD-1 inhibitor
Nivolumab2015Melanoma, nonsmall-cell lung cancer, small cell lung cancer, renal cell carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, Hodgkin lymphoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability/mismatch repair
Pembrolizumab2015Melanoma, nonsmall-cell lung cancer, squamous cell carcinoma of the head and neck, Hodgkin lymphoma, renal cell carcinoma, urothelial carcinoma, gastric cancer, cancers with microsatellite instability, mismatch repair, cervical cancer, primary mediastinal B cell lymphoma
Cemiplimab2018Cutaneous squamous cell cancer
PD-L1 inhibitor
Atezolizumab2016Nonsmall-cell lung cancer, urothelial carcinoma
Avelumab2017Merkel-cell carcinoma, urothelial carcinoma
Durvalumab2018Urothelial carcinoma, nonsmall-cell lung cancer
  • CRC, colorectal carcinoma; CTLA-4, cytotoxic T lymphocyte–associated protein 4; PD-1, programmed cell death protein 1; PD-L1, PD-ligand 1.